Anavex Life Sciences Corp (AVXL)

[rx7171]

And the EMA has ZERO additional AD drug applications in hand and none of us here see any in the foreseeable future.

For European AD patients and their caregivers Blarcamasine is the only hope for that foreseeable future and let’s assume the CHMP doesn’t let them down.